STOCK TITAN
  1. Home
  2. News
  3. VTRS

Viatris Inc - VTRS STOCK NEWS

Welcome to our dedicated news page for Viatris (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Viatris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Viatris's position in the market.

News
Viatris Partners With Comfort Cases to Support Youth in U.S. Foster Care
Rhea-AI Summary
Viatris (VTRS) partners with Comfort Cases to pack 1,000 backpacks for children in foster care as part of its Impact Week Anniversary Celebration. This is the second consecutive year of the partnership, with the company expanding its efforts by also packing backpacks at its offices in Washington, D.C. and New York City. Viatris' mission of empowering people worldwide to live healthier at every stage of life extends beyond medicines to making the world a better place by building healthier communities. Comfort Cases founder, Rob Scheer, personally connected to the cause, expressed gratitude for Viatris' support in ensuring foster children have the support and resources they need to thrive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
partnership
-
News
Viatris to Participate in the Jefferies London Healthcare Conference
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) to Participate in Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences
-
News
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive Phase III results for YUPELRI in China, demonstrating efficacy and safety for COPD patients. The study shows a statistically significant increase in trough FEV1 compared to placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
clinical trial
News
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) and Theravance Biopharma, Inc. (NASDAQ: TBPH) announce positive results from the YUPELRI Phase III clinical trial in China, demonstrating efficacy and safety for COPD patients. Top-line results show a statistically significant increase in trough FEV1 versus placebo, supporting a regulatory filing in China in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
clinical trial
-
News
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges[1]
Rhea-AI Summary
Viatris Inc. (NASDAQ: VTRS) reports total revenues of $3.94 billion, U.S. GAAP net earnings of $332 million, adjusted EBITDA of $1.36 billion, U.S. GAAP net cash provided by operating activities of $834 million, and free cash flow of $738 million for the quarter. Strong results signal continuation of growth journey with second consecutive quarter of year-over-year operational revenue growth on a divestiture-adjusted basis. Revises full-year total revenues guidance range solely to reflect the expected negative impact of foreign exchange. On track to complete all planned divestitures by the end of the first half of 2024. Board of Directors declares quarterly dividend of $0.12 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
-
News
Viatris to Host Webinar: The Power of Partnership to Address Antimicrobial Resistance
Rhea-AI Summary
Viatris Inc. is hosting a webinar called 'The Power of Partnership to Address Antimicrobial Resistance (AMR)' on November 14, 2023. AMR is a significant threat to global health and economic development, potentially causing more deaths than HIV/AIDS and malaria worldwide. The World Health Organization estimates that deaths due to AMR could reach 10 million people a year by 2050 without action. The webinar will include discussions with experts from the AMR Industry Alliance and the University of Pennsylvania.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
partnership conferences
News
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
Rhea-AI Summary
Viatris Inc. has been named to Forbes' list of World's Best Employers 2023 for the third consecutive year. The recognition highlights the company's commitment to empowering people worldwide and creating a strong culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
News
Viatris Named to Forbes' Annual List of the World's Best Employers for the Third Year in a Row
Rhea-AI Summary
Viatris Inc. has been named to Forbes' list of World's Best Employers 2023 for the third consecutive year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.09%
Tags
none
-
News
Rajiv Malik to Retire as President of Viatris Effective April 1, 2024
Rhea-AI Summary
Viatris President Rajiv Malik to retire in April 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
News
Viatris Named to 3BL's 100 Best Corporate Citizens of 2023 Ranking
Rhea-AI Summary
Viatris Named to 3BL's 100 Best Corporate Citizens Ranking
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
Stock VTRS logo
Viatris Inc

Nasdaq:VTRS

VTRS Rankings

#666 Ranked by Market Cap
#2929 Ranked by Stock Gains
#786 Ranked by Dividends

VTRS Stock Data

13.46B
1.18B
0.35%
83.36%
3.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Canonsburg

About VTRS

mylan is a global pharmaceutical company committed to setting new standards in healthcare. working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. in addition, we offer a wide range of antiretroviral therapies, upon which nearly 50% of hiv/aids patients in developing countries depend. we also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time. learn more at mylan.com.